Stryker Bets $835M on Unapproved IVL Innovator Amplitude Vascular Systems
Stryker
Medical Device R&D, Production, and Sales Company
Johnson & Johnson
Medical Device R&D and Manufacturer
Last month,International orthopedic giant Stryker announces the signing of a definitive agreement to acquire Amplitude Vascular Systems (AVS)Recently, the price of this acquisition was disclosed: approximately $435 million in cash, plus up to $400 million in milestone payments.The total transaction amount is nearly 5.7 billion RMB.
It is worth mentioning that this AVS, which was acquired by Stryker for a large sum,Its core product, the Pulse IVL System, has not yet obtained product registration., has only obtained the FDA's Investigational Device Exemption (IDE) and is still in the critical clinical trial stage.
Why Would Stryker Spend $5.7 Billion on a Company with No Products on the Market Yet, Only in the Critical Clinical Trial Stage?
Behind this,Not only do global medical device giants highly value the innovation track in cardiovascular interventions—especially in the field of intravascular lithotripsy (IVL)—but it also conveys a firm consensus:Truly innovative devices that address clinical pain points are inherently high-value, high-premium, and have a long lifecycle.
Global Giants Heavily Invest in IVL
How Can an Unapproved Product Be Worth 5.7 Billion?
In the treatment of peripheral artery disease (PAD) and coronary artery disease, severe calcification can not only cause difficulty in device delivery, balloon dilation failure, and poor stent apposition,Directly affecting the success rate of surgery and patient prognosis, it also significantly increases the difficulty of operation for doctors.
Intravascular Lithotripsy (IVL Technology) involves the release of special pressure waves through a balloon catheter to precisely fragment vascular calcifications, clearing obstacles for subsequent treatment.It is the most promising and clinically recognized innovative technology for the treatment of calcified lesions currently.
And in the global medical device market, Stryker is not the only giant that has heavily invested in the IVL track:
In 2024, Johnson & Johnson (J&J) acquired Shockwave Medical, the pioneer of the IVL track, for $13.1 billion, integrating it into its core pipeline with the goal of building it into a blockbuster platform with annual sales of $1 billion.
In 2025, Boston Scientific acquired Bolt Medical for $664 million, securing the laser IVL platform, and obtained FDA 510(k) clearance in April of the same year, officially launching commercialization.
Unlike the two aforementioned products, AVS's Pulse IVL System is undoubtedly a "rising star" in the IVL field.Its unique technical approach of using pulsed CO₂ to generate pressure waves, compared with Shockwave's electrohydraulic shock waves and Bolt's laser acoustic pressure wavesForm a distinct competitive advantage.
China's IVL Track: From Blank to Explosion
The Golden Layout Period for Distributors
And the heavy investment of global giants has long been transmitted to the Chinese market——China's IVL sector is rapidly transitioning from a "product scarcity phase" to a "commercialization boom phase.", this is the best window period for dealer layout.
China is a country with a high prevalence of cardiovascular diseases, with over ten million patients suffering from peripheral arterial disease, of which more than 40% have moderate to severe calcified lesions. Traditional treatment options have limited efficacy, and there is an urgent clinical need for innovative devices like IVL.
Moreover, patients with severe limb ischemia (CLI) at the end stage of peripheral artery disease highly overlap with those undergoing orthopedic lower limb surgery.After the IVL product is launched, it can quickly打通 orthopedics and vascular intervention departments, reusing existing resources.
Currently, the IVL system from Shockwave, a subsidiary of Johnson & Johnson, has been approved by the NMPA. Meanwhile, IVL devices and catheters from several local companies have also been successively approved for marketing.The wave of domestic substitution accelerates, and the next 2-3 years will witness a concentrated surge of domestically produced products entering the market.
At present, the global cardiovascular intervention innovation track is in a period of rapid growth, and the Chinese market has enormous potential. According to industry data, the market size of cardiovascular intervention consumables in China was approximately 32 billion yuan in 2023.It is expected to exceed 40 billion yuan by 2026, with the proportion of innovative devices continuing to rise, becoming the core driver of growth.
Dealers who make early investments in innovative products like IVL are tying themselves to high-growth sectors. In the future, they can benefit from the triple rewards of product commercialization, localization of production in China, and market expansion, achieving a leap from "small dealers" to "leading industry service providers."
However, how to find high-potential innovative medical device newcomers?
The White Paper of "Breaking Boundaries, Leading the Way: China's Medical Device Innovation in a Global Context," which took three years to complete, has selectedHigh-Growth Main Tracks in 16 Major Medical Device Fields: Cardiovascular Interventions, Surgical Robots, Medical Imaging, etc., combing through more than 400 innovative medical device products that are globally popular,Not only does it thoroughly analyze the current market situation, technological trends, and competitive landscape, but it also incorporates the latest capital dynamics such as Stryker's acquisition, extracting specific opportunities for domestic hospital terminals reflected by the new wave overseas.
The First White Paper on Innovative Medical Devices in the Industry
Original Price: 499 RMB
Special Promotion Activity for Customer Appreciation
Only 269 yuan!!!
?Click on the image for more details?
*Advertisement
Currently,This white paper has sold over 1,500 copies online and is hailed by dealers as the "battle map" for filtering high-potential products and finding truly powerful manufacturers.
Instead of getting caught in the fierce competition within China, it's better to shift focus towards high-value innovations on the global stage that address real clinical pain points.
If you are looking for the next worthwhile category to invest in,Whether you want to get ahead in the new wave of China-produced vascular intervention, or seize the opportunity in cutting-edge niche markets like minimally invasive energy platforms and neuromodulation, this white paper can significantly shorten your market research and product screening cycle.
?Click on the image for more details?
